New Jersey is currently home to 1712 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
NCT04656496
Recruiting
Pediatric cancer survivors are at an increased risk of excessive weight gain and reduced exercise behaviors with the potential for this risk to worsen over time. With over 80% of pediatric cancer patients living to adulthood, many pediatric cancer survivors experience long-term health consequences such as heart disease - the leading cause of death in this population. The purpose of this clinical research study is to teach parents/caregivers skills that will help prevent and reduce the problems... Read More
Gender:
All
Ages:
Between 5 years and 14 years
Trial Updated:
09/26/2023
Locations: Hackensack Meridian Health, Hackensack, New Jersey
Conditions: Obesity, Childhood, Cancer, Survivorship
Register for Updates
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
NCT05360680
Recruiting
This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A*0201 positive patients with WT1 positive recurrent/metastatic solid tumors who have failed conventional therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/25/2023
Locations: Carol G. Simon Cancer Center - Morristown Medical Center, Morristown, New Jersey
Conditions: Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
Register for Updates
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
NCT02949284
Recruiting
This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate cancer undergoing surgery. Androgen can cause the growth of prostate cancer cells. Hormone therapy using androgen receptor antagonist ARN-509, abiraterone acetate, and gonadotropin-releasing hormone analog (GnRH agonist) may fight prostate cancer by lowering the levels of... Read More
Gender:
Male
Ages:
All
Trial Updated:
09/24/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Register for Updates
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
NCT05481151
Recruiting
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV
Gender:
All
Ages:
18 years and above
Trial Updated:
09/22/2023
Locations: Astera HealthCare, East Brunswick, New Jersey
Conditions: Polycythemia Vera
Register for Updates
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
NCT04849364
Recruiting
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).
Gender:
All
Ages:
18 years and above
Trial Updated:
09/22/2023
Locations: Summit Health, Berkeley Heights, New Jersey
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
Molecular Genetics Studies of Cancer Patients and Their Relatives
NCT04185935
Recruiting
This trial studies the genetic and behavioral factors that may contribute to the development of specific cancers and how these factors may affect the outcome of the disease in patients with a history of cancer and their relatives.
Gender:
All
Ages:
All
Trial Updated:
09/21/2023
Locations: Hunterdon Medical Center, Flemington, New Jersey
Conditions: Malignant Neoplasm
Register for Updates
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
NCT04080284
Recruiting
Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths. Patients with USC share many genomic and clinical characteristics with patients who has serous ovarian cancer. The objective of this study is to evaluate the efficacy of maintenance Niraparib regimen in patients with advanced or platinum sensitive recurrent uterine serous carcinoma. Additionally, the investigators aim to further describe the safety of this regimen. The investigators hypothesize that Nirap... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
09/20/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Endometrial Cancer, Papillary Serous Endometrial Carcinoma, Uterine Serous Carcinoma, Endometrial Carcinoma, Cancer of the Endometrium
Register for Updates
Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer
NCT05358704
Recruiting
To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI and to Escalate Complete Response for Rectal Cancer patients.Go through laboratory and medical tests to verify eligibility to enter the study, receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) prior to surgery and undergo laboratory tests and study procedures on specified days during the study per... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/17/2023
Locations: RWJBarnabas Health - Monmouth Medical Center, Lakewood, New Jersey
Conditions: Cancer of Rectum
Register for Updates
Translating Scientific Evidence Into Practice Using Digital Medicine and Electronic Patient Reported Outcomes
NCT04345393
Recruiting
Delivery of healthcare has been traditionally limited to in-person visits or hospitalizations, while patients spend the majority of their time at home or work. Digital Medicine (e.g. apps, remote monitoring, telemedicine, patient reported outcomes) has the potential to bridge this gap, but the question remains as to how to translate it to mainstream practice while providing individualized recommendations to improve population health across organizations. Through the creation of a Digital Transfo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/17/2023
Locations: RxHealth, Secaucus, New Jersey
Conditions: Inflammatory Bowel Disease (IBD)
Register for Updates
Pilot Study of Stomach Cancer Early Detection and Prevention With Endoscopy
NCT05566899
Recruiting
Screening esophagogastroduodenoscopy (EGD )provides three distinct opportunities to decrease gastric cancer (GC) morbidity and mortality. has potential to discover cancer in early stages before the onset of symptoms, leading to higher rates of survival. Second, premalignant lesions such as adenomatous polyps, intestinal metaplasia and dysplasia can be discovered and removed with local resection, akin to polypectomies during screening colonoscopies, preventing the development of cancer. Third, EG... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
09/16/2023
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Gastric Cancer
Register for Updates
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
NCT05545111
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, multi-arm, multi-stage inpatient study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of NBI-1117568 compared with placebo in adult subjects with a primary diagnosis of schizophrenia, who are experiencing an acute exacerbation or relapse of symptoms.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
09/15/2023
Locations: Neurocrine Clinical Site, Berlin, New Jersey
Conditions: Schizophrenia
Register for Updates
Conditioning SCID Infants Diagnosed Early
NCT03619551
Recruiting
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono... Read More
Gender:
All
Ages:
Between 0 years and 2 years
Trial Updated:
09/15/2023
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: SCID
Register for Updates